Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2022 Earnings Conference Call November 3, 2022 8:00 AM ET

Company Participants

Holly Manning - Investor Relations

Brian Goff - Chief Executive Officer

Sarah Gheuens - Chief Medical Officer and Head, Research and Development

Richa Poddar - Chief Commercial Officer

Cecilia Jones - Chief Financial Officer

Conference Call Participants

Marc Frahm - Cowen

Mark Breidenbach - Oppenheimer

Andy Berens - SVB

Andrea Tan - Goldman Sachs

Danielle Brill - Raymond James

Operator

Good day and thank you for standing by and welcome to Q3 2022 Agios Pharmaceuticals, Inc. Earnings Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded. I would now like to hand the conference over to your speaker today, Holly Manning. Please go ahead.

Holly Manning

Thank you, operator. Good morning, everyone, and welcome to Agios’ third quarter 2022 conference call. You can access slides for today’s call by going to the Investors section of our website, agios.com. With me on the call today with prepared remarks are Brian Goff, our Chief Executive Officer; Dr. Sarah Gheuens, our Chief Medical Officer and Head of Research and Development; Richa Poddar, our Chief Commercial Officer; and Cecilia Jones, our Chief Financial Officer.

Before we get started, I would like to remind everyone that some of the statements we make on this call will include forward-looking statements. Actual events and results could differ materially from those expressed or implied by any forward-looking statements as a result of various risks, uncertainties and other factors, including those set forth in our most recent filings with the SEC and any other future filings that we may make with the SEC.

With that, I will turn the call over to Brian.

Brian Goff

Thanks, Holly and good morning, everyone. It’s a privilege to join you today on my first Agios financial results call as Chief Executive Officer nearly 3 months after assuming the role in August.

Agios has a longstanding legacy of scientific excellence and clinical execution and is on the cusp of broadening its ability to change the treatment landscape of rare and genetically defined diseases. With the recent launch of PYRUKYND and its extensive clinical and preclinical pipeline, the opportunity that lies ahead for Agios and the patients it serves is exciting [Technical Difficulty] the company from the very beginning.

Since joining in August as I have dug into the business and met so many of our talented team, my optimism and excitement for the future of Agios has grown for several reasons, first, the strength of the culture and patient orientation is even better than I perceived during my diligence process. The emphasis on our shared mission of improving lives is palpable across all functions within the organization and part of the fabric of the decisions we make, the people we hire and the reason we come to work every day. Second, for a company of our size, the depth and breadth of activity across all areas of the business is remarkable. 2022 has been a year of execution with 5 pivotal studies and 2 early-stage trials underway, an ongoing commercial launch in the U.S. and active filing in the EU and Great Britain and advancing preclinical pipeline and broad business development efforts to continue to build out our pipeline.